If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
=== Historiography === Historiography of communist states is polarised. According to John Earl Haynes and Harvey Klehr, historiography is characterised by a split between traditionalists and revisionists. "Traditionalists", who characterise themselves as objective reporters of an alleged totalitarian nature of communism and communist states, are criticised by their opponents as being anti-communist, even fascist, in their eagerness on continuing to focus on the issues of the Cold War. Alternative characterisations for traditionalists include "anti-communist", "conservative", "Draperite" (after Theodore Draper), "orthodox", and "right-wing"; Norman Markowitz, a prominent "revisionist", referred to them as "reactionaries", "right-wing romantics", "romantics", and "triumphalist" who belong to the "HUAC school of CPUSA scholarship". According to Haynes and Klehr, "revisionists" are more numerous and dominate academic institutions and learned journals. A suggested alternative formulation is "new historians of American communism", but that has not caught on because these historians describe themselves as unbiased and scholarly and contrast their work to the work of anti-communist traditionalists whom they would term biased and unscholarly. Academic Sovietology after World War II and during the Cold War was dominated by the "totalitarian model" of the Soviet Union, stressing the absolute nature of Stalin's power. The "revisionist school" beginning in the 1960s focused on relatively autonomous institutions which might influence policy at the higher level.
Hurley showed tremendous form throughout the TAC Cup, showing his all-round quality for the Northern Knights. He was named All-Australian in 2007 and backed it up with another selection after the 2008 AFL Under 18 Championships and was also selected in the TAC Cup Team of the Year in both seasons. He made his debut against the Port Adelaide Power in round 1, 2009, and was nominated twice as the AFL Rising Star nominee, in round 20 of that season, and round 18 the following year, both times against St Kilda. After his match-winning four goal performance against Hawthorn in round 22, 2009, Leigh Matthews said, "Very few young talls have the physical maturity to match it with their older and stronger opponents, which is why the brilliant early form of young Bomber Michael Hurley is quite amazing." Ahead of the 2010 season, Hurley inherited the famous number 18 guernsey from retired club great Matthew Lloyd. The following four seasons saw Hurley's form fluctuate due to injury and the constant shuffling of his position in the team between both ends of the ground. He averaged 22 goals per season, and spent just as much time playing in the back line on some of the opposition's best key forwards, where his precise kicking and attacking flair out of the back half were noticeable on numerous occasions. The 2014 season brought with it a permanent role for Hurley as a key defender, the position for which he was initially drafted. This newfound positional consistency allowed him to really begin to shine as a footballer.
== Safety and toxicity == Excess pre‑formed vitamin A from supplements or fortified foods can cause hypervitaminosis A, characterized acutely by nausea and raised intracranial pressure and chronically by liver injury and teratogenicity. Retinyl acetate shares these dose‑dependent toxicities because it is quantitatively hydrolyzed to retinol. Phototoxicity and photo‑isomerization are significantly lower than for unesterified retinol but can occur in formulations lacking UV stabilizers.
Sources: en.wikipedia.org
Also known as a "bonderizer" bonding agents (spelled dentin bonding agents in American English) are resin materials used to make a dental composite filling material adhere to both dentin and enamel. Bonding agents are often methacrylates with some volatile carrier and solvent like acetone. They may also contain diluent monomers. For proper bonding of resin composite restorations, dentin should be conditioned with polyacrylic acids to remove the smear layer, created during mechanical treatment with dental bore, and expose some of the collagen network or organic matrix of dentin. Adhesive resin should create the so-called hybrid layer (consisting of a collagen network exposed by etching and embedded in adhesive resin). This layer is an interface between dentin and adhesive resin and the final quality of dental restoration depends greatly on its properties. Modern dental bonding systems come as a “three-step system”, where the etchant, primer, and adhesive are applied sequentially; as a “two-step system”, where the etchant and the primer are combined for simultaneous application; and as a “one-step system”, where all the components should be premixed and applied in a single application (so-called sixth generation of bonding agents).
== Nitrogen-13 == Nitrogen-13 (13N) has a half-life of a little under ten minutes. It is produced in the atmosphere when gamma rays (for example from lightning) knock neutrons out of nitrogen-14. 13N decays to 13C, emitting a positron. The positron quickly annihilates with an electron, producing two gamma rays of about 511 keV. After a lightning bolt, this gamma radiation dies down with a half-life of 10 minutes, but these low-energy gamma rays go on average only about 90 metres through the air, so they may only be detected for a minute or so as the "cloud" of 13N and 15O floats by, carried by the wind. Nitrogen-13 plays a significant role in the CNO cycle, which is the dominant source of energy in main sequence stars more massive than 1.5 times the mass of the Sun. Nitrogen-13 is used in positron emission tomography in the form of 13N-labelled ammonia, for example for myocardial perfusion imaging. It can be produced with a medical cyclotron, using a target of pure water with a trace amount of ethanol. The reactants are oxygen-16 (present as H2O) and a proton, and the products are nitrogen-13 and an alpha particle (helium-4):
== Drug development risks == Risks that could affect the further development of tecemotide published in the annual reports of Oncothyreon (grantor of the license) and Merck KGaA (license holder; responsible for clinical development, marketing and manufacturing) are listed in the following sections.
== Practice areas == Pharmacists practice in a variety of areas including community pharmacies, infusion pharmacies, hospitals, clinics, insurance companies, medical communication companies, research facilities, pharmaceutical companies, extended care facilities, psychiatric hospitals, and regulatory agencies. Pharmacists themselves may have expertise in a medical specialty.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.